Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
2.988
+0.138 (4.85%)
Aug 13, 2025, 2:50 PM - Market open

Company Description

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.

The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer.

Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S.

aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N.

gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus.

The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025.

Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Evaxion A/S
Evaxion logo
CountryDenmark
Founded2008
IPO DateFeb 5, 2021
IndustryBiotechnology
SectorHealthcare
Employees46
CEOBirgitte Rono

Contact Details

Address:
Dr. Neergaards Vej, 5th Floor
Horsholm, 2970
Denmark
Phone45 31 31 97 53
Websiteevaxion.ai

Stock Details

Ticker SymbolEVAX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$10.00
CIK Code0001828253
CUSIP Number29970R303
ISIN NumberUS29970R3030
SIC Code2836

Key Executives

NamePosition
Dr. Birgitte Rono Ph.D.Interim Chief Executive Officer and Chief Scientific Officer
Andreas Holm MattssonFounder and Chief AI Officer
Thomas Frederik Schmidt M.Sc.Chief Financial Officer

Latest SEC Filings

DateTypeTitle
Aug 11, 20256-KReport of foreign issuer
Jul 25, 20256-KReport of foreign issuer
Jul 17, 20256-KReport of foreign issuer
Jul 11, 20256-KReport of foreign issuer
Jul 2, 20256-KReport of foreign issuer
Jun 25, 20256-KReport of foreign issuer
Jun 3, 20256-KReport of foreign issuer
May 27, 20256-KReport of foreign issuer
May 23, 20256-KReport of foreign issuer
May 22, 20256-KReport of foreign issuer